Michela Errico analyses:
- Biotechnology: state of the art
- IP situation in Europe and in Italy
- Patentability requirements: •DNA sequences •Stem Cells •Antibodies •Others
2. 2
…about me
Education
- European Patent Attorney Qualification
- Italian Patent Attorney Qualification
- PhD Biologiacal Processes and Biomolecules
Molecular Biology Degree
Professional Experience
1998-2009 - Researcher in Molecular and Cell
Biology, Genetics and Developmental Biology
2009 to date – Patent Attorney at Bugnion SpA
SISSA, May 10 2016
3. Outline
• Biotechnology: state of the art
• IP situation in Europe and in Italy
•Patentability requirements
• DNA sequences
• Stem Cells
• Antibodies
• Others
SISSA, May 10 2016
4. Definition
BIOTECHNOLOGY is defined here as any
technological application that uses biological
systems, living organisms, or derivatives
thereof, to make or modify products or
processes for specific use.
Art. 2 of Biological Diversity Convention
https://www.cbd.int/convention/articles/default.shtml?a=cbd-02
4SISSA, May 10 2016
5. Modern Biotechnology
1953
We have discovered the
secret of life!!
1960
The beginning of the
Genetic Engineering Era
SISSA, May 10 2016
7. Legal Basis
European Directive 98/44 on the Legal
Protection of Biotechnological Inventions
Industrial Property Code
D.Lgs n. 131, 2010
Implementing Regulation
D.Lgs n.33, 2010
European Patent Convention
SISSA, May 10 2016
8. - To create a harmonized legal context in Europe
- To attract investors in biotechnological field
- To secure several ethical issues
- To define the exclusions for ethical reasons
- To give definitions in the new technical area
Aims of the Biotech Directive
SISSA, May 10 2016
July 30, 2000 was the deadline for
implementing the Directive by the EU
member states (Art 15 of Biotech
Directive)
9. La presentazione integrale è disponibile
a richiesta sul sito Bugnion
Consulenza in proprietà industriale e
intellettuale, registrazione e tutela di marchi,
brevetti e di tutti i beni immateriali delle imprese
www.bugnion.it